Instalab

Antral Follicle Count Test

A direct look at how many eggs your ovaries still have, beyond what a blood test alone can show.

Should you take a AFC test?

This test is most useful if any of these apply to you.

Thinking About When to Have Kids
This test shows you, in real time, how many eggs your ovaries still have, so you can plan timing or freezing decisions with actual data.
Preparing for IVF or Egg Freezing
Your count is among the strongest predictors of how your ovaries will respond to stimulation, shaping protocol and dose decisions.
Working Through a PCOS Workup
A high follicle count is one of the diagnostic features of polycystic ovary syndrome and helps confirm or rule out the condition.
After Chemotherapy or Pelvic Radiation
Cancer treatment can reduce ovarian reserve, and this test shows directly how much follicle pool remains after therapy.

About Antral Follicle Count

If you have ever wondered how much time your ovaries actually have left, this is the test that gives you a direct look. A trained sonographer counts the small fluid-filled follicles in both of your ovaries, and that number tells you, in real time, roughly how many eggs are currently in the recruitable pool.

Unlike a hormone level pulled from a tube of blood, this is an image of your ovaries themselves. The number it produces is one of the most concrete measures of ovarian reserve available to you, and it can change how you think about fertility timing, IVF planning, and conditions like PCOS or endometriosis.

What This Test Actually Measures

AFC (antral follicle count) is the total number of small follicles, typically between 2 and 10 millimeters across, visible in both ovaries on a transvaginal ultrasound. These are the follicles that have already left the resting pool and are competing for the chance to release an egg in an upcoming cycle. They are also the follicles that respond to fertility drugs.

The count is best done with a high-frequency vaginal probe and a systematic sweep of each ovary in two planes. Newer 3D techniques and even at-home virtual scans (guided remotely by a trained technologist) produce counts that are equivalent to standard in-clinic 2D scans, with image quality and patient satisfaction shown to be non-inferior in a randomized study of 56 women.

AFC was once thought to require testing on cycle days 2 to 5, but newer evidence shows that a count taken on any day of your menstrual cycle gives similar predictive value for ovarian response, oocyte yield, and correlation with AMH (anti-Mullerian hormone, a blood hormone reflecting the same follicle pool). This makes the test far more practical than it used to be.

Why Your Number Matters for Fertility

AFC is among the strongest single predictors of how your ovaries will respond to stimulation in IVF. In a meta-analysis pooling results across studies, AFC outperformed basal FSH (follicle-stimulating hormone, the pituitary signal that drives follicle growth) for predicting poor ovarian response, with sensitivities and specificities near 90% at common thresholds.

In a large study of 9,484 women classified under the POSEIDON framework for low-prognosis patients, AFC and AMH together stratified women into categories that genuinely change treatment decisions. In another analysis of 89,002 IVF patients, AFC combined with age sharpened the prediction of poor response well beyond age alone.

One important caveat: AFC predicts how many eggs you can recruit, not whether you will get pregnant. Egg quality and embryo health depend more strongly on age than on follicle count. The number tells you about the size of the pool, not the health of any individual egg.

What AFC Reveals About Underlying Biology

In a prospective study of 89 premenopausal women that compared imaging to actual ovarian tissue, AFC was associated with the size of the primordial follicle pool, the deep reserve of eggs you were born with. This supports AFC as a real biological marker, not just a procedural count.

The follicles being counted contain granulosa cells (the support cells around each egg) that produce AMH, a hormone you can also measure in blood. AFC and AMH are tightly correlated and capture overlapping information. When they disagree, AFC has been shown in a study of 1,121 IVF patients to be the more reliable predictor of actual ovarian response.

Diminished Ovarian Reserve

A low AFC indicates diminished ovarian reserve, which has real consequences. In a meta-analysis of recurrent pregnancy loss, low AMH and low AFC were both associated with higher odds of miscarriage. A single-center study of 773 women undergoing IVF found that diminished ovarian reserve was linked to higher rates of chromosomally abnormal embryos, which helps explain why declining reserve translates into harder cycles even when eggs are retrieved.

Endometriosis lowers AFC. A meta-analysis of women with endometriosis confirmed reduced antral follicle count, lower AMH, and higher FSH compared with controls, with the effect strongest in advanced disease and in ovaries directly affected by endometriomas.

Cancer survivors who received chemotherapy show lower AFC and AMH than women without that history. In a study of 3,904 childhood cancer survivors, cyclophosphamide, procarbazine, and abdominal or pelvic radiotherapy were each independently associated with abnormal ovarian reserve markers, with dose-response relationships for procarbazine and radiation.

PCOS and High AFC

A high AFC has different meaning entirely. Polycystic ovarian morphology, one of the diagnostic features of polycystic ovary syndrome, is defined by an excess of small antral follicles. The Androgen Excess and PCOS Society task force has proposed a follicle number per ovary of at least 25 (using modern high-frequency probes) as a research threshold for polycystic ovarian morphology in adult women.

In women with PCOS undergoing IVF, a high AFC is also one of the strongest predictors of ovarian hyperstimulation syndrome, a serious complication of fertility treatment. A study of 2,699 women with PCOS undergoing IVF identified AFC as a major predictor of OHSS severity, which directly changes how stimulation protocols should be designed.

Reconciling High Versus Low: This Is a Phenotype Test

It can feel confusing that both high and low AFC signal problems. The key is to understand that AFC is not a good-number versus bad-number test. It is a phenotype indicator. A low count tells you the recruitable pool is small, which matters most if you want to have children. A high count tells you the pool is unusually large, which often reflects an underlying ovulatory disorder. Different patterns carry different risks, and the same number means different things in different bodies.

When Results Can Be Misleading

AFC depends on who is doing the counting and how. A study of 203 women showed that intra-observer and inter-observer reproducibility are generally high, but agreement declines when follicle counts are very high. Operator skill and probe frequency matter.

  • Cycle-to-cycle variation: AFC shows more intra-cycle and inter-cycle variability than AMH in a study of 121 subfertile women. A single count is a snapshot, not a trend.
  • Body size: In a study of 36 late-reproductive-age women, obesity was associated with lower AMH, and other research links higher BMI to changes in ovarian reserve markers. Body composition can shift the picture without necessarily reflecting true reserve.
  • Recent surgery: Cystectomy for endometrioma can transiently affect AFC; one randomized study of 48 women showed cystectomy reduced follicle count and ovarian volume in operated ovaries.
  • Operator and equipment: Probe frequency and 2D versus 3D technique can shift counts, especially in ovaries with many follicles.

Tracking Your Trend

AFC is more useful as a trend than as a single number. Because counts vary between cycles and observers, a single reading can mislead. A baseline measurement, a repeat in 6 to 12 months, and then annual tracking gives you a real trajectory you can act on. If you are actively trying to preserve fertility or undergoing treatment that affects the ovaries, retesting every 3 to 6 months can make sense.

An age-related nomogram built from 3,821 women shows that AFC peaks in the early twenties and declines with age. Knowing where your number falls relative to others your age, and how it changes over time, is more informative than any one isolated count.

What to Do With an Unexpected Result

If your AFC is lower than expected for your age, pair it with an AMH blood test, FSH, and estradiol drawn early in your cycle. The combination paints a clearer picture than any single marker. Consider seeing a reproductive endocrinologist, especially if you are planning to delay pregnancy or have a family history of early menopause.

If your AFC is high, ask whether you also have signs of PCOS (irregular cycles, hyperandrogenism, or insulin resistance). In that case, fasting glucose, fasting insulin, HbA1c (a marker of average blood sugar over three months), and androgens like total testosterone and DHEA-S round out the workup. A high count in someone planning IVF requires careful protocol selection to avoid hyperstimulation.

If AFC and AMH disagree, AFC is generally the more reliable predictor of how your ovaries will actually behave during stimulation, based on data from 1,121 IVF patients. The discordance itself is worth investigating, and a fertility specialist can help interpret it.

What Moves This Biomarker

Evidence-backed interventions that affect your AFC level

Decrease
Chemotherapy with cyclophosphamide, procarbazine, or pelvic radiotherapy
In a study of 3,904 female childhood cancer survivors, cyclophosphamide, procarbazine, and abdominal or pelvic radiotherapy were each independently associated with abnormal ovarian reserve markers including reduced AFC, with dose-response relationships for procarbazine and radiation. A prospective study of 71 breast cancer patients also showed significant decreases in AFC, AMH, and ovarian volume after systemic chemotherapy. These treatments genuinely cause loss of ovarian reserve.
MedicationStrong Evidence
Increase
Selenium plus vitamin E supplementation
In a randomized controlled trial of 70 infertile women with occult premature ovarian insufficiency, supplementation with selenium and vitamin E significantly increased antral follicle count, AMH, and mean ovarian volume compared with placebo, without reported side effects. This is one of the few interventions shown in a randomized trial to genuinely raise AFC in women with reduced ovarian reserve.
SupplementModerate Evidence
Increase
GnRH agonist (goserelin) co-administration during chemotherapy
In a prospective cohort study of 242 young breast cancer patients, goserelin co-administered during chemotherapy provided ovarian reserve protection compared with chemotherapy alone, potentially improving recovery of AFC and AMH after treatment.
MedicationModerate Evidence
Decrease
Surgical removal of ovarian endometriomas (cystectomy)
In a randomized study of 48 women with bilateral endometriomas, laparoscopic ovarian cystectomy significantly reduced AFC and ovarian volume in operated ovaries. A meta-analysis on endometrioma surgery confirmed reductions in AMH after cystectomy, though one earlier meta-analysis found no significant effect on AFC specifically. The procedure can damage residual healthy ovarian tissue.
MedicationModerate Evidence
Increase
DHEA (dehydroepiandrosterone) supplementation
A meta-analysis of DHEA priming in women with poor ovarian response found that DHEA supplementation may improve antral follicle count and reduce basal FSH levels before IVF. A separate small randomized pilot of 32 poor responders did not show significant improvement in ovarian response markers or IVF outcomes, so evidence is mixed and the effect on live birth in randomized trials alone is not significant.
SupplementModest Evidence
Increase
Coenzyme Q10
In a meta-analysis on antioxidants and fertility in women with ovarian aging, CoQ10 supplementation improved fertility outcomes, with stronger effects at lower doses and depending on age and baseline ovarian reserve. A randomized controlled trial of 100 women with poor ovarian response also evaluated CoQ10 effects on ovarian reserve markers and ICSI outcomes.
SupplementModest Evidence
Increase
Melatonin
In a randomized controlled trial of 68 women with diminished ovarian reserve, melatonin supplementation improved oocyte quality and assisted reproductive technology outcomes, likely by reducing oxidative stress (cellular damage from unstable molecules) in the follicles. Effects on AFC specifically were part of the broader ovarian reserve assessment.
SupplementModest Evidence
Increase
Pro-fertility dietary pattern (Mediterranean-style, higher antioxidant intake)
In a cross-sectional study of 185 overweight and obese women from the Lifestyle and Ovarian Reserve cohort, greater adherence to a pro-fertility diet was associated with improved ovarian reserve markers. A separate study of 567 women attending a fertility center found that higher lycopene intake was associated with higher AFC, while higher retinol intake was inversely associated with AFC in women under 35.
DietModest Evidence
Increase
Folate intake, especially from supplements
In a study of 552 women attending a fertility center, higher folate intake (particularly from supplements) was associated with modestly higher ovarian reserve markers including AFC. The effect is small but consistent with broader nutritional support of follicle development.
SupplementModest Evidence
Decrease
Obesity and high BMI
In a systematic review on nutritional status and ovarian reserve, higher BMI was associated with reduced ovary function and increased need for assisted reproductive techniques. A study of 183 women undergoing ovarian stimulation also found that obesity may impair response. Effects on AFC are modest but real and may operate through changes in AMH, inflammation, or insulin signaling.
LifestyleModest Evidence

Frequently Asked Questions

References

36 studies
  1. Broekmans F, De Ziegler D, Howles C, Gougeon a, Trew G, Olivennes FFertility and Sterility2010
  2. Chang MY, Chiang C, Hsieh T, Soong Y, Hsu KHFertility and Sterility1998
  3. Razafintsalama M, Bah M, Amand G, Vienet-legue L, Pietin-vialle C, Bry-gauillard H, Pinto M, Pasquier M, Jung C, Levaillant J, Massin NHuman Reproduction2021